WeTrials
Recruiting

A Phase II Study of Naxitamab Added to Induction Therapy for Subjects With Newly Diagnosed High-Risk Neuroblastoma

What is this study?

This study is testing whether adding a special antibody medicine called naxitamab to standard chemotherapy can help fight a type of childhood nerve cell cancer called high-risk neuroblastoma. Doctors hope this combination will work better than standard treatment alone to help the body destroy cancer cells.

Who can participate?

This study is for children who have been newly diagnosed with high-risk neuroblastoma, usually based on their age and specific genetic features of the tumor. Children must be at least one year old and cannot have received previous extensive cancer treatments.

What will happen?

Participants will receive five cycles of standard multi-agent chemotherapy combined with naxitamab, which is a medicine designed to help the immune system find and attack the cancer. Doctors will closely monitor your child's health, response to treatment, and overall safety throughout the process.

Where and when?

The study is currently active and recruiting patients at several medical centers in cities including Birmingham, Little Rock, and Oakland. You can check with your care team to see if a participating location is convenient for your family.

Key Points
  • 1Tests a new medicine called naxitamab alongside standard chemotherapy
  • 2Designed for children with newly diagnosed high-risk neuroblastoma
  • 3Currently recruiting patients at multiple medical centers in the United States

Related links

Outside pages about this study, checked by our team

Suggest a link
Conditions Studied
This study is investigating treatments for the following conditions
Neuroblastoma

This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.